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ABSTRACT
Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with tyrosine kinase
inhibitor lapatinib can induce a compensatory HER3 increase, which may attenuate antitumor efﬁcacy.
Therefore, we explored in vivo HER3 tumor status assessment after lapatinib treatment with zirconium-89
(89Zr)-labeled anti-HER3 antibody mAb3481 positron emission tomography (PET). Lapatinib effects on
HER3 cell surface expression and mAb3481 internalization were evaluated in human breast (BT474, SKBR3)
and gastric (N87) cancer cell lines using ﬂow cytometry. Next, in vivo effects of daily lapatinib treatment
on89Zr-mAb3481 BT474 and N87 xenograft tumor uptake were studied. PET-scans (BT474 only) were made
after daily lapatinib treatment for 9 days, starting 3 days prior to 89Zr-mAb3481 administration.
Subsequently, ex vivo 89Zr-mAb3481 organ distribution analysis was performed and HER3 tumor levels
were measured with Western blot and immunohistochemistry. In vitro, lapatinib increased membranous
HER3 in BT474, SKBR3 and N87 cells, and consequently mAb3481 internalization 1.7-fold (BT474), 1.4-fold
(SKBR3) and 1.4-fold (N87). 89Zr-mAb3481 BT474 tumor uptake was remarkably high at SUVmean 5.6§0.6
(51.8§7.7%ID/g) using a 10 mg 89Zr-mAb3481 protein dose in vehicle-treated mice. However, compared to
vehicle, lapatinib did not affect 89Zr-mAb3481 ex vivo uptake in BT474 and N87 tumors, while HER3 tumor
expression remained unchanged. In conclusion, lapatinib increased in vitro HER3 tumor cell expression,
but not when these cells were xenografted. 89Zr-mAb3481 PET accurately reﬂected HER3 tumor status.
89Zr-mAb3481 PET showed high, HER3-speciﬁc tumor uptake, and such an approach might sensitively
assess HER3 tumor heterogeneity and treatment response in patients.
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Human epidermal growth factor receptor (HER) 3 (also
known as ERBB3) is an important regulator of cell growth
and differentiation.1,2 Upon ligand binding, HER3 interacts
with other HER family members, such as epidermal growth
factor receptor (EGFR) and HER2, to form heterodimers. In
contrast, HER2:HER3 dimers are also formed in a ligand-
independent manner.3 HER3 heterodimerization leads to
activation of downstream signaling, such as the PI3K/Akt
and RAS-MAPK pathways, thereby prompting biological
processes involved in tumor growth and maintenance.1 The
importance of HER3 in human cancers has long been
underestimated due to its impaired tyrosine kinase activity
and relatively low tumor expression. However, EGFR:HER3
and HER2:HER3 heterodimers are the most potent among
HER family signaling complexes.4,5 HER3 is overexpressed
in human breast, colorectal, gastric, head and neck and
ovarian cancers, and its expression is associated with poor
prognosis.1,6 In addition, HER3 is strongly implicated as a
key mediator of resistance to various treatments, including
HER-targeting agents, chemotherapy, estrogen receptor
antagonists and RAF/MEK inhibitors.1,7
Targeting HER family proteins is an important treatment
strategy for many solid tumors, with treatment options consist-
ing of monoclonal antibodies (mAbs) and tyrosine kinase
inhibitors (TKIs).8 EGFR/HER2 TKI lapatinib is indicated for
treatment of trastuzumab-refractory HER2-positive metastatic
breast cancer patients; however, intrinsic or acquired lapatinib
resistance frequently occurs in these patients.8 Preclinical stud-
ies showed that lapatinib treatment of HER2-positive breast
cancer xenograft models can lead to a rapid compensatory
increase in HER3 expression, signaling activity and plasma
membrane relocalization.9,10 Two weeks of lapatinib treatment
increased HER3 expression as measured immunohistochemi-
cally (IHC) in HER2-overexpressing breast cancers of newly
diagnosed patients, which might attenuate the antitumor action
of lapatinib.9 Additional HER3 blockade might overcome resis-
tance to HER-targeting agents, as suggested by a study showing
that combining anti-HER3 mAbs with HER2 inhibitors
enhanced tumor growth inhibition in HER2-positive breast
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cancer xenografts.11 Hence, multiple HER3-targeted mAbs are
in various phases of clinical development.1 HER3 expression
might be a potential biomarker to monitor and predict treat-
ment efﬁcacy of HER-targeting therapies, given its compensa-
tory role in HER signaling and overexpression.
Because HER3 expression is dynamic, an equally dynamic
assessment of HER3 tumor status might be indicated, rather
than invasive static techniques such as IHC measurements of
biopsies. Non-invasive three-dimensional whole body positron
emission tomography (PET) imaging of HER3 over time could
potentially address this. Molecular characteristic such as HER3
can be imaged with PET, using antibodies radiolabeled with zir-
conium-89 (89Zr, t1/2 D 78.4 h). The physical half-life of 89Zr
matches the time antibodies require for optimal tumor vs. non-
tumor binding.12 Previous pre(clinical) studies have shown
HER3 antibody PET imaging can safely provide information
about anti-HER3 mAb distribution and tumor HER3 expres-
sion levels.13–17 However, to date no (pre)clinical studies have
investigated the treatment effects of HER2-targeting drugs on
the dynamics of HER3 expression using molecular imaging.
The aim of this study was to investigate the feasibility of in vivo
whole body HER3 status assessment after lapatinib treatment
in human breast and gastric cancer xenografts using HER3
mAb 89Zr-mAb3481 PET imaging.
Results
In vitro effects of lapatinib on HER3 levels and mAb3481
internalization in BT474, SKBR3 and N87 cells
HER2-ampliﬁed breast cancer cell lines BT474 and SKBR3, and
gastric cancer cell line N87, were ﬁrst examined for membra-
nous HER3 expression by ﬂow cytometry. All cell lines
expressed HER3, with the highest cell surface levels found in
BT474 and SKBR3 (Fig. 1A). Three-day exposure to 250 nM
lapatinib resulted in a 1.6 § 0.1, 1.8 § 0.2 and 1.7 § 0.4 fold
increase in membranous HER3 of BT474 (Fig. 1B), SKBR3
(Fig. 1C) and N87 (Fig. 1D) cells, respectively. Internalization
experiments showed that 58 § 1% (BT474), 72 § 5% (SKBR3)
and 65 § 4% (N87) of the mAb3481-HER3 complexes were
internalized. Exposure of cells to 250 nM lapatinib for 72 hours
resulted in a 74 § 4%, 43 § 33% and 42 § 23% increase of
absolute internalized mAb3481 in BT474, SKBR3 and N87
cells, respectively, when compared to controls (Suppl. Fig. 1).
In vivo effects of 25 mg/kg lapatinib on BT474 HER3
expression and 89Zr-mAb3481 uptake
Both 25 and 50 mg/kg lapatinib inhibited tumor growth in
BT474 xenografted pilot mice (Suppl. Fig. 2); therefore, these
doses were selected for evaluation of their effects on HER3
expression in vivo by 89Zr-mAb3481 PET. Lapatinib effects on
HER3 expression and 89Zr-mAb3481 tumor uptake were ﬁrst
evaluated using 25 mg/kg lapatinib and a 10 mg 89Zr-mAb3481
tracer protein dose in BT474 xenografted mice. Tumor uptake
144 h pi for both treatments and vehicle were similar on 89
Zr-mAb3481 PET scans, with a SUVmean of 5.6 § 0.6 and 5.3
§ 1.3 for vehicle and 25 mg/kg lapatinib-treated mice, respec-
tively (P D 0.73, Fig. 2A, B). Ex vivo results were equal to in
vivo ﬁndings, a similar high (P D 0.54, Fig. 2C) and HER3-spe-
ciﬁc BT474 tumor uptake was found for both vehicle (51.8 §
7.7%ID/g) and 25 mg/kg lapatinib-treated mice (53.3
§ 12.4%ID/g), compared to 10.8 § 3.1 and 10.8 § 4.0%ID/g
for 111In-mAb002 controls, respectively. Injected tracer protein
doses for vehicle and lapatinib-treated mice were comparable
(Suppl. Fig. 3C). 89Zr-mAb3481 in the blood pool was low in
both vehicle and 25 mg/kg lapatinib-treated mice at 1.8 § 2.2
and 2.2 § 2.3%ID/g, respectively, compared to 13.1 § 5.3 and
12.5 § 4.0%ID/g, respectively, for 111In-mAb002 control
(Fig. 2D, Suppl. Fig. 4A, Suppl. Fig. 4B). No differential effect
was observed for tumor growth in lapatinib- versus vehicle-
treated mice (Fig. 2E, Suppl. Fig. 3A). HER3 expression in
BT474 tumors remained unchanged after lapatinib therapy, as
measured by IHC and Western blot (Fig. 2F, G).
In vivo effects of 50 mg/kg lapatinib on BT474 HER3
expression and 89Zr-mAb3481 uptake
Due to the lack of observable tumor inhibition, low remaining
89Zr-mAb3481 blood pool levels at sacriﬁce, and a lack of lapa-
tinib effects on HER3 expression and tumor tracer uptake in
the 25 mg/kg lapatinib cohort, a second HER3 modulation was
undertaken. This second cohort was treated with either vehicle
or 50 mg/kg lapatinib to induce a more robust tumor inhibi-
tion, and a tracer protein dose of 25 mg and smaller starting
tumor size were used in an attempt to increase the residual
89Zr-mAb3481 blood pool. Increase in tracer protein dose to
25 mg 89Zr-mAb3481 led to a lower in vivo and ex vivo tumor
uptake than observed for the 10 mg tracer dose. Again, no dif-
ference for vehicle and 50 mg/kg lapatinib cohorts was
observed, with SUVmeans of 4.0 § 0.6 and 3.9 § 0.8, respec-
tively, for BT474 tumors 144 h pi (PD 0.79, Fig. 3A, B). Despite
the tracer protein dose increase, ex vivo biodistribution showed
a high HER3-speciﬁc BT474 tumor uptake of 46.9 § 4.7% ID/g
and 46.2 § 7.7%ID/g for vehicle and lapatinib, respectively,
conﬁrming PET data (Fig. 3C). Blood levels for the 25 mg tracer
protein dose were higher than observed for the 10 mg tracer
dose at 7.3 § 2.3% ID/g and 6.9 § 1.5%ID/g, respectively, for
89Zr-mAb3481, with 17.0 § 2.1%ID/g and 14.3 § 3.2%ID/g
111In-mAb002 observed for vehicle and lapatinib-treated mice,
respectively (Fig. 3D, Suppl. Fig. 4C, 4D). Injected tracer pro-
tein doses for vehicle and lapatinib-treated mice were compara-
ble (Suppl. Fig. 3D). Tumor growth was affected, starting from
day 7 after commencing 50 mg/kg lapatinib treatment
compared to vehicle (Fig. 3E, Suppl. Fig. 3B). Ex vivo, HER3
expression in BT474 tumors remained unchanged after 50
mg/kg lapatinib for 9 days, as measured by IHC and Western
blot (Fig. 3F, G).
In vivo effects of 25, 50 and 100 mg/kg lapatinib on N87
HER3 expression and 89Zr-mAb3481 uptake
Next, the gastric cancer N87 xenograft model was used to test
whether the above ﬁndings hold true in a second model. Ex
vivo biodistribution showed preferential (13.3 § 2.5% ID/g)
89Zr-mAb3481 N87 tumor uptake, compared to 5.8 § 0.1% ID/
g for 111In-mAb002 controls in vehicle-treated mice (Suppl.






























uptake in N87 xenografts correlated with the 2.5-fold lower in
vitro HER3 surface expression (Fig. 1A). Treatment with 25, 50
or 100 mg/kg lapatinib had no effects on tumor uptake com-
pared to vehicle-treated mice (Suppl. Fig. 5A). A dose-depen-
dent trend was observed between tumor growth and lapatinib
treatment (Suppl. Fig. 5C). The 10 mg 89Zr-mAb3481 tracer
protein dose for N87 xenografted animals resulted in compara-
ble blood levels (Suppl. Fig. 5D) to those observed in the 25 mg
tracer protein dose in the BT474 xenograft model, likely due to
lower HER3-driven tracer tumor uptake. HER3 IHC showed
faint staining, likely due to lower expression (Fig 1A), and no
observable differences between treatment groups in N87
tumors (Suppl. Fig. 5E). Human glyceraldehyde 3-phosphate
dehydrogenase (GAPDH)-normalized HER3 expression in
N87 tumors was not signiﬁcantly altered after 25, 50 and
100 mg/kg lapatinib for 9 days, as shown by Western blot
(Suppl. Fig. 5 F).
Discussion
Here, we describe the properties of 89Zr-mAb3481, a HER3
antibody PET tracer, with remarkably high contrast and
speciﬁc tumor uptake in human breast and gastric cancer
xenografts. Lapatinib increased HER3 expression in vitro,
but not in human breast and gastric cancer xenografts, while
89Zr-mAb3481 accurately reﬂected in vivo HER3 tumor sta-
tus post lapatinib treatment.
In the preclinical setting, HER3 imaging has been exten-
sively studied using afﬁbodies and antibodies labeled with vari-
ous radioisotopes for PET and single positron emission
computed tomography (SPECT). HER3 afﬁbody-based SPECT
and PET tracers 111In-HEHEHE-Z08698-NOTA, 111In-
HEHEHE-Z08699-NOTA, 99mTc(CO)3-HEHEHE-Z08699 and
68Ga-HEHEHE-Z08698-NOTA showed tumor uptakes of 5.0
§ 0.6, 5 § 1, 1.7 § 0.6 and 2.6 § 0.4% ID/g, respectively, in
BT474 xenografts. Tumor-to-blood ratios of afﬁbody tracers
ranged between 7–25, while tumor uptake could be saturated
by 70 mg cold afﬁbody.18–20 The 89Zr-mAb3481 tumor-to-
blood ratio was higher at 53.7 § 31.7 for the 10 mg protein
dose and similar at 7.0 § 2.4 for the 25 mg protein dose in vehi-
cle-treated mice compared to these afﬁbodies. Bispeciﬁc HER2/
HER3 tracer 111In-DTPA-Fab-PEG24-HRG, on the other
hand, showed 7.0 § 1.2, 4.4 § 0.9 and 7.8 § 2.1%ID/g tumor
uptake in SK-OV-3, MDA-MB-468 and BT474 xenografts.21
Among antibody-based tracers, glycoengineered human HER3
antibody 89Zr-lumretuzumab showed the highest uptake
(27.5%ID/g) in human head and neck cancer FaDu xenografts
at the lowest (0.05 mg/kg) tracer protein dose tested.13 64Cu-
DTPA-patritumab showed uptake in BxPC3 human pancreatic
cancer xenografts, which could be blocked by 800 mg cold pat-
ritumab.22 Anti-human HER3 rat IgG2a mAb 89Zr-Mab#58
Figure 1. Effects of lapatinib treatment on membranous HER3 expression. (A) Membranous HER3 expression levels in BT474, SKBR3 and N87 cells. (B-D) Effects of 72 hours
lapatinib treatment (50, 250 and 500 nM) on HER3 cell surface expression levels in BT474, SKBR3 and N87 cells. Data points are mean C SD. All experiments were per-
formed in triplicate. ( P < 0.05,  P < 0.01,  P < 0.001 compared to control).





























showed 12.2 § 4.5%ID/g, and 17.8%ID/g tumor uptake in sta-
bly human HER3-overexpressing rat hepatoma HER3/RH7777
and colorectal cancer tissue-originated spheroid C45 xeno-
grafts, respectively.14 Compared to these preclinical HER3 trac-
ers, 89Zr-mAb3481 had both the highest absolute tumor uptake
observed and a tumor-to-blood contrast comparable or even
superior to HER3 afﬁbody-based tracers. High 89Zr-mAb3481
HER3-speciﬁc tumor uptake, when compared to other anti-
body-based tracers, might be explained by its murine IgG1 ori-
gin. Athymic nude mice, as used in our study, have functional
B-cells and thus antibody production, with circulating IgG1
levels reported at 1.25 § 0.15 mg/mL serum.23 Therefore,
unspeciﬁc sink organs might already be saturated by circulating
murine IgG1 from the host animal, resulting in higher 89Zr-
mAb3481 tracer availability for tumor uptake, in contrast to
non-murine IgG antibody tracers.
A full 89Zr-mAb3481 protein dose escalation experiment
was not performed in our study. However, 10 mg
89Zr-mAb3481 in the 25 mg/kg lapatinib experiment already
showed excellent BT474 tumor uptake. Tracer blood levels in
this experiment were depleted to 2.2 § 2.3%ID/g in lapatinib-
treated mice, after unexpectedly fast tumor growth, paired with
the high speciﬁc BT474 tumor uptake. Tumor growth inhibi-
tion, increase in 89Zr-mAb3481 tumor uptake and ex vivo
HER3 upregulation were not observed in the 25 mg/kg lapati-
nib 89Zr-mAb3481 PET experiment. Therefore, the lapatinib
dose was increased to 50 mg/kg for a second cohort to induce a
more robust tumor inhibition and possibly HER3 induction.
Because low 89Zr-mAb3481 blood levels could hamper visuali-
zation of the potential extra HER3 expression, tracer protein
dose was increased to 25 mg. Indeed, increased tracer protein
dose raised 89Zr-mAb3481 blood levels to 6.9 § 1.5%ID/g for
lapatinib-treated mice at sacriﬁce, and only marginally lowered
BT474 tumor tracer uptake. However, 89Zr-mAb3481 tumor
uptake and HER3 tumor expression remained unaltered after
50 mg/kg lapatinib treatment. Observed differences in tumor
uptake between 25 and 50 mg/kg lapatinib validation cohorts
were »10% based upon biodistribution data, while in vivo
uptake data showed a differential of »30% in SUVmean. This
discrepancy between ex vivo biodistribution and in vivo PET
Figure 2. Results for vehicle and 25 mg/kg lapatinib (lap)-treated BT474 xenograft-bearing mice. (A) Representative coronal 89Zr-mAb3481 HER3 PET scans, 6 days post
tracer injection. (B) In vivo 89Zr-mAb3481 tumor and blood pool uptake, 6 days post tracer injection, expressed as SUVmean. (C) Ex vivo
89Zr-mAb3481 and 111In-mAb002
tumor uptake data, presented as %ID/g. (D) Ex vivo 89Zr-mAb3481 and 111In-mAb002 BT474 blood pool data, presented as %ID/g. (E) Tumor volumes during treatment.
(F) Ex vivo tissue analysis. HER3 immunohistochemical staining for tumor tissues. (G) HER3 Western blots of xenograft tumor lysates. Each band represents a tumor from a






























uptake data might be attributed to the partial volume effect,24
as tumors of the 25 mg/kg lapatinib group were 2.2-fold larger
at an average of 492 § 218 mm3, compared to only 226 § 49
mm3 for the 50 mg/kg cohort. N87 xenografts showed lower
89Zr-mAb3481 tumor uptake than BT474, in accordance with
lower in vitro HER3 expression of this cell line. In line with our
ﬁndings for BT474, lapatinib treatment did not increase ex vivo
HER3 protein levels, or 89Zr-mAb3481 tumor uptake in N87
xenografted mice, compared to vehicle.
Imaging of HER3 response to treatment has been performed
before. Dual EGFR/HER3 antibody 89Zr-MEHD7945A
revealed an increase in triple-negative breast cancer patient-
derived xenograft tumor uptake from 5.74 § 2.40% ID/g to
9.76 § 1.51% ID/g after pan-AKT inhibitor GDC-0068
Figure 3. Results for vehicle and 50 mg/kg lapatinib (lap)-treated BT474 xenograft-bearing mice. (A) Representative coronal 89Zr-mAb3481 HER3 PET scans, 6 days post
tracer injection. (B) In vivo 89Zr-mAb3481 tumor and blood pool uptake, 6 days post tracer injection, expressed as SUVmean. (C) Ex vivo
89Zr-mAb3481 and 111In-mAb002
tumor uptake data, presented as %ID/g. (D) Ex vivo 89Zr-mAb3481 and 111In-mAb002 blood pool data, presented as % ID/g. (E) Tumor volumes during treatment, with  P
<0.05 and  P <0.01. (F) Ex vivo tissue analysis. HER3 immunohistochemical staining of tumor tissues. (G) HER3 Western blots of xenograft tumor lysates. Each band rep-
resents a tumor from a single mouse. Immunoreactive spots were quantiﬁed by densitometric analysis and normalized using anti-human GAPDH, normalized to vehicle.





























treatment.25 The effects of GDC-0068 effects on HER3 alone
were imaged with 64Cu-anti-HER3-F(ab’), which showed
MDA-MB-468 tumor uptake increased from SUVmean of 0.35§
0.02 for vehicle to 0.73§0.05 (P<0.01), three days after treat-
ment initiation.26 In vitro, 48 hours 5 mM GDC-0068 treatment
resulted in 74%, 102%, and 65% increased HER3 surface
expression in MDA-MB-468, HCC-70 and MCF-7 human
breast cancer cells, respectively.26 Imaging with lower molecu-
lar weight tracers, e.g., afﬁbodies or F(ab)2, might be beneﬁcial
for imaging of fast or short-lived effects, due to their shorter
biological half-life and faster tumor accumulation, compared to
full-length antibody tracers.
In our study, lapatinib treatment in vitro led to a similar 60–
70% increase in HER3 membrane expression, albeit at a lower
concentration of 250 nM, while 5 mM lapatinib potently inhib-
ited BT474 and N87 cells in culture. In vivo, tumors remained
sensitive to lapatinib treatment, as shown by continued tumor
growth suppression in lapatinib-treated animals. Therefore, it is
conceivable that any lapatinib-induced increase in HER3 expres-
sion in BT474 and N87 tumors might have been offset by tumor
cell inhibition. In addition, in a previous report it was demon-
strated that even continuous lapatinib treatment (100 mg/kg) for
28 days did not result in an increase of HER3 expression in
BT474 xenografts.9,10 In contrast to cell cultures, drug plasma
concentration cannot be tightly controlled in mice, with preclini-
cal data showing highly variable plasma concentrations for single
30 and 60 mg/kg oral lapatinib doses in mice, ranging from
»1–5 mM at 1 h, to »50–500 nM at 16 h after administration.27
Therefore, the therapeutic window of lapatinib might have been
too narrow to upregulate HER3 expression in vivo, withoutmajor
effects on tumor proliferation. 89Zr-mAb3481 PET did, however,
accurately reﬂect the actual HER3 tumor status after lapatinib
treatment in BT474 and N87 xenografts, as both HER3 expres-
sion and 89Zr-mAb3481 tumor uptake remained unchanged.
Similar to the results of this study, gastric cancer patients
showed unaltered HER3 mRNA levels after lapatinib plus cape-
citabine therapy; however, elevated HER3 mRNA levels at base-
line did correlate with an increased response rate to the
combination.28 In ovarian cancer, low HER3 mRNA levels rep-
resented a more sensitive phenotype for the HER2 dimerization
blocking mAb pertuzumab and gemcitabine treatment.29 Iden-
tiﬁcation of tumor HER3 levels and heterogeneity might there-
fore pose an attractive option for patient stratiﬁcation. The
highly speciﬁc tumor uptake in our study indicates that changes
and variation in HER3 expression might be sensitively assessed
using a humanized version of 89Zr-mAb3481 for HER3 PET.
This measurement of HER3 tumor expression is likely also
feasible in the clinic, as several clinical HER3 PET imaging
studies already showed feasibility for HER3 heterogeneity
assessment. Human HER3 antibody 64Cu-patritumab revealed
tumor uptake in cancer patients, but also showed high liver
uptake, which decreased after pre-administration of 9 mg/kg
cold unlabeled patritumab.15 Clinical application of glycoengi-
neered human HER3 antibody 89Zr-lumretuzumab showed
tumor speciﬁc uptake, which was partly saturated by therapeu-
tically relevant doses of 400, 800 and 1600 mg unlabeled lumre-
tuzumab.16 Furthermore, HER3 antibody 89Zr-GSK2849330
was evaluated in patients with advanced HER3 expressing solid
tumors (ClinicalTrials.gov Identiﬁer NCT02345174).
In conclusion, 89Zr-mAb3481 HER3 PET imaging revealed a
remarkably high speciﬁc tumor uptake, with superior contrast
compared to other preclinical HER3 imaging agents. Lapatinib
treatment induced HER3 upregulation in human breast cancer
cell lines in vitro, but not in corresponding xenograft tissues. In
vivo HER3 status was accurately reﬂected by 89Zr-mAb3481
PET. Sensitive 89Zr-HER3 antibody PET imaging of HER3 in
response to various treatments or HER3 expression screening
might pose an attractive option for the clinic.
Materials and methods
Cells lines and materials
Human breast cancer cell lines BT474 and SKBR3, and human
gastric cancer cell line N87 were obtained from the American
Type Culture Collection. BT474 and N87 were cultured in Ros-
well Park Memorial Institute-1640 medium (RPMI-1640,
Gibco) supplemented with 10% fetal calf serum (FCS, Bodinco
BV) and SKBR3 in Dulbecco’s Modiﬁed Eagle Medium
(DMEM, Gibco) high glucose C 10% FCS. Cells were incubated
at 37C in a humidiﬁed atmosphere with 5% CO2. HER2-
ampliﬁed cell lines BT474, SKBR3 and N87 are highly sensitive
(half maximal inhibitory concentration < 0.1 mM) to lapati-
nib.30,31 Anti-human mouse HER3 IgG1 mAb mAb3481 (cata-
log # MAB3481) and corresponding isotype control mouse
IgG1 mAb002 (catalog # MAB002) were purchased from R&D
Systems. For mAb treatments and ﬂow cytometric measure-
ments, a total concentration of 20 mg/mL was used, unless oth-
erwise indicated. Lapatinib-di-p-toluenesulfonate (LC Labs)
was dissolved in dimethyl sulfoxide, stored at ¡20C and
diluted in fresh medium for use. Final concentration of
dimethyl sulfoxide in experiments never exceeded 0.1% v/v.
For animal experiments, lapatinib-di-p-toluenesulfonate was
suspended fresh daily in 0.5% hydroxymethyl propyl cellulose
4000 mPa.s (Hospital Pharmacy, UCMG), 0.1% Tween 80
(Sigma).
Flow cytometry
Analysis of HER3 expression was performed using ﬂow cytom-
etry. Cells were harvested in phosphate-buffered saline (PBS:
9.7 mM Na2HPO4, 1.6 mM KH2PO4, 150 mM NaCl, pH D 7.2)
containing 2% FCS (FACS buffer) and kept on ice prior to use.
mAb3481 in FACS medium served as HER3 primary antibody,
while bound primary antibody was detected using a PE-conju-
gated goat anti-mouse secondary polyclonal antibody
(1010–09, SouthernBiotech) diluted 1:50 in FACS medium. To
determine surface expression and internalization of mAb3481,
tumor cells were incubated on ice with mAb3481. Subse-
quently, HER3 surface expression was measured in mAb3481-
incubated cells, which were washed with ice-cold FACS buffer
and incubated with secondary antibody for 1 hour on ice. To
determine the non-internalized fraction, mAb3481 incubated
cells were washed twice with ice-cold FACS buffer, incubated
in original culture medium at 378C for 2 hours and subse-
quently incubated with secondary antibody for 1 hour on ice.
The internalized fraction of mAb3481 was determined by sub-






























surface expression. Duplicate samples were measured for each
condition, and corrected for background ﬂuorescence and
unspeciﬁc binding of secondary antibody. Measurements were
performed on a BD Accuri C6 (BD Biosciences). Data analysis
was performed with FlowJo v10 (Tree Star) and surface recep-
tor expression was expressed as mean ﬂuorescent intensity
(MFI).
Western Blots
After appropriate treatments, cells were washed twice with ice-
cold PBS and lysed in Mammalian Protein Extraction Reagent
(M-PER, Thermo Scientiﬁc), supplemented with phosphatase
and protease inhibitors (Thermo Scientiﬁc), for 60 minutes,
scraped and cellular contents transferred to micro centrifuge
tubes for storage at ¡20C until analysis. For preparation of
xenograft whole-cell lysates, tumor pieces were homogenized
by mechanical disruption in M-PER lysis buffer. Protein con-
centrations of lysates were determined using the Bradford pro-
tein assay.32 Protein samples from total cell lysates (20 or
50 mg) were subjected to electrophoretic separation on 7.5 or
10% polyacrylamide gels and transblotted onto polyvinylidine
ﬂuoride membranes (Millipore). Blots were blocked at room
temperature for 1 hour in Tris-buffered saline (TBS)/Tween 20
(TBS-T) (0.05%), containing 5% bovine serum albumin. Block-
ing was followed by incubation with 1:1000 rabbit anti-HER3
(Clone C17, Santa Cruz Biotechnology), 1:10000 mouse mono-
clonal anti-actin (clone C4, MP Biomedicals) or 1:10000 rabbit
anti-human anti-GAPDH (EPR6256, Abcam). Blots were sub-
sequently washed and incubated with 1:1500 HRP-anti-mouse
or HRP-anti-rabbit antibodies (P0260 & P0448, Dako). Detec-
tion was performed using Lumi-Light Western blotting sub-
strate (Roche Diagnostics Nederland BV). Images were
captured using a digital imaging system (Bio-Rad). Densito-
metric analysis on immunoreactive spots was performed with
ImageJ v1.47, normalized using actin or GAPDH and expressed
as fold increase versus control.
89Zr-mA3481 HER3 tracer production
mAb3481 was incubated with a 1:10 molar ratio of antibody to
tetraﬂuorphenol-N-succinyldesferal (Df, ABX GmbH, Ham-
burg, Germany) as described earlier,12 yielding on average 2.96
Df bound per mAb3481 molecule. Df-mAb3481 conjugates
were checked for aggregation and fragmentation by a Waters
size-exclusion high performance liquid chromatography) sys-
tem, equipped with a dual wavelength absorbance detector, in-
line radioactivity detector and TSK-GEL G3000SWXL column
(JSB, Eindhoven, The Netherlands). PBS (140 mmol/L NaCl, 9
mmol/L Na2HPO4, 1.3 mmol/L NaH2PO4; pH D 7.4) was used
as mobile phase.
89Zr labeling was performed as described earlier, using clinical
grade 89Zr (Perkin Elmer). Maximum attainable speciﬁc activity
was determined by radiolabeling Df-mAb3481 conjugate with
varying speciﬁc activities (50, 100, 250, 500 and 1000 MBq
89Zr/mg conjugate).33 Radiochemical purity (RCP) of 89Zr-label-
ing was assessed by trichloroacetic acid precipitation test.34
Mouse IgG1 isotype control mAb002 (R&D Systems) was
used as unspeciﬁc control tracer molecule in in vivo
experiments. For indium-111 (111In) labeling, mAb002 was
conjugated with p-SCN-Bn-DTPA (Macrocyclics) as described
earlier.35 Radiolabeling was performed using 111In-chloride
(Mallinckrodt). Radiochemical purity of 111In-mAb002 labeling
was checked by instant thin layer chromatography using 0.1 M
citrate buffer pH 6.0 as eluent.
Animal experiments
Nude mice (male BALB/cOlaHsd-Foxn1nu, Envigo) were used.
Mice were subcutaneously (sc) implanted with 0.36 mg 17b-
estradiol 90-day release pellets (Innovative Research of Amer-
ica), were used for BT474 xenograft animal experiments. All
inoculations were performed sc using 5106 cells in 300 mL of a
1:1 mix of PBS and high growth factor Matrigel (Corning), and
xenografts were allowed to establish to volumes of at least 100–
200 mm3 before start of experiments. Tumor size and animal
weight were measured twice weekly.
BT474 xenografted mice were treated with vehicle or 25 mg/
kg lapatinib (both conditions n D 9) daily via oral gavage until
sacriﬁce. Three days after start of treatment, mice received
10 mg 89Zr-mAb3481 (3–4 MBq), combined with 10 mg 111In-
mAb002 (1 MBq) unspeciﬁc control via the penile vein.
Another cohort of BT474 xenografted mice received vehicle or
50 mg/kg lapatinib (both conditions n D 8) daily via oral
gavage until sacriﬁce. Three days after start of treatment mice
received 25 mg 89Zr-mAb3481 (3–4 MBq) and 25 mg 111In-
mAb002 (1 MBq) via penile vein injection. MicroPET scans
were made 6 days post tracer injection (pi) of both cohorts
using a Focus 220 PET scanner (CTI Siemens). Scans were
reconstructed and in vivo quantiﬁcation performed using
AMIDE v1.0.4.36 MicroPET data are presented as mean stan-
dardized uptake value (SUVmean). After PET scans, mice were
sacriﬁced and organs of interest collected for ex vivo biodistri-
bution analysis.
The N87 xenograft model was chosen as a second model
because pilot data showed that SKBR3 xenografts were less
developed and too sensitive to lapatinib treatment (data not
shown). N87 xenografted mice were treated with vehicle 25, 50
or 100 mg/kg lapatinib (n D 3 for each condition) daily via oral
gavage until sacriﬁce. Three days after start of treatment, mice
received 10 mg 89Zr-mAb3481 (1.0–1.5 MBq), combined with
10 mg 111In-mAb002 (1 MBq) unspeciﬁc control via the penile
vein. N87 xenografted mice were sacriﬁced for biodistribution
6 days post tracer injection.
Organs and standards of the injected tracer were counted in
a calibrated well type LKB-1282-Compu-gamma system (LKB
WALLAC) and weighed. After decay correction, ex vivo tissue
activity was expressed as the percentage of injected dose per
gram tissue (%ID/g). Xenograft tumor tissues were either for-
malin-ﬁxed and parafﬁn-embedded for IHC or frozen for sub-
sequent analysis. All animal experiments were approved by the
Institutional Animal Care and Use Committee of the Univer-
sity of Groningen.
Ex vivo analyses
Formalin-ﬁxed, parafﬁn-embedded tissue slices (3–4 mm) were
deparafﬁnized and rehydrated. Heat-induced antigen retrieval





























was performed in 10 mM TRIS/EDTA (pH 9.0) at 100C for
15 minutes and endogenous peroxidase was blocked by 30-
minute incubation with 0.3% H2O2 in PBS. Slides were stained
for HER3 with a 1:50 dilution of rabbit polyclonal antibody
(Clone SC-285, Santa Cruz Biotechnology). Incubation with
secondary antibody (EnVision System, Dako HRP; Dako) was
performed for 30 minutes, followed by application of diamino-
benzidine chromogen for 10 minutes. Hematoxylin counter-
staining was applied routinely, and hematoxylin & eosin
(H&E) staining served to analyze tissue viability and morphol-
ogy. Digital scans of slides were acquired by a NanoZoomer
2.0-HT multi slide scanner (Hamamatsu) and analyzed with
NanoZoomer Digital Pathology viewer software.
Statistical analyses
Data were assessed using GraphPad Prism (GraphPad v5.0) for
differences using the two-sided Mann-Whitney test for non-
parametric data and the two-sided unpaired Student’s T-test or
two-way ANOVA followed by Bonferroni post-test for
parametric data. P-values < 0.05 were considered signiﬁcant,
with  indicating P < 0.05 and  denoting P < 0.01.
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